Primitive Neuroectodermal Tumor — Trials

Primitive Neuroectodermal Tumor — Trials · CancerIndex

Clinical trials

Registered studies

673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 146
Recruiting: 80
Ph III recruiting: 8
Growth YoY: −33.3%
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 32.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (86)

clinicaltrialsPublishedShowing 51–100 of 673 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05650749	GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2)	enrolling by invitation	Phase 1	45	Stephan Grupp MD PhDOTHER	1	Aug 14, 2026	clinicaltrials
NCT01326104	Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH)	completed	Phase 2	26	University of FloridaOTHER	1	Aug 13, 2026